TCRT (Alaunos Therapeutics) Total Assets: $1.88 Mil (As of Mar. 2026)


TCRT Alaunos Therapeutics Inc TCRT
28 GF Score
Price $2.08
GF Value $0.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics Total Assets?

Alaunos Therapeutics TCRT -4.37% 28 Total Assets is $1.88 Mil as of Mar. 2026. GuruFocus rates TCRT with a GF Score™ of 28/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Alaunos Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $1.88 Mil.

During the past 12 months, Alaunos Therapeutics's average Total Assets Growth Rate was -15.10% per year. During the past 3 years, the average Total Assets Growth Rate was -60.60% per year. During the past 5 years, the average Total Assets Growth Rate was -50.60% per year. During the past 10 years, the average Total Assets Growth Rate was -24.30% per year.

During the past 13 years, Alaunos Therapeutics's highest 3-Year average Total Assets Growth Rate was 748.60%. The lowest was -60.60%. And the median was 8.80%.

Total Assets is connected with ROA %. Alaunos Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -165.97%. Total Assets is also linked to Revenue through Asset Turnover. Alaunos Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Alaunos Therapeutics  (NAS:TCRT) Total Assets Explanation

Total Assets is connected with ROA %.

Alaunos Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-4.024/( (2.966+1.883)/ 2 )
=-4.024/2.4245
=-165.97 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Alaunos Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (2.966+1.883)/ 2 )
=0/2.4245
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Alaunos Therapeutics Total Assets Related Terms

Alaunos Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics Total Assets Chart

Alaunos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 94.87 64.94 8.26 2.76 2.97

Alaunos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.12 4.74 3.72 2.97 1.88
TCRT
28GF Score
Alaunos Therapeutics Inc TCRT
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alaunos Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Alaunos Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=2.153+0.813
=2.97

Alaunos Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=1.288+0.595
=1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $1.88 Mil mean?
Alaunos Therapeutics (TCRT) has a Total Assets of $1.88 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Alaunos Therapeutics and its competitors.
Is Alaunos Therapeutics' Total Assets too high?
Alaunos Therapeutics' current Total Assets is $1.88 Mil. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' Total Assets compare to DRMA and MBIO?
Alaunos Therapeutics' Total Assets of $1.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current Total Assets is $1.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.08 — trading 205.9% above its estimated fair value. The current Total Assets is $1.88 Mil. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current Total Assets is $1.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $2.08 is trading 205.9% above its estimated GF Value™ of $0.68. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • Total Assets: $1.88 Mil
  • GF Value™: $0.68 vs. price of $2.08 (205.9% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score

Get the complete analysis for TCRT

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$0.68
GF Value